Cipla Ltd.
Snapshot View

920.30 +38.00 ▲4.3%

30 July 2021, 04:00:00 P.M.
Volume: 349,527

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.cipla.com
Financial Indicators
Market Cap 71,170.06 Cr.
Earnings per share (EPS) 29.81 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 29.59 Trailing Twelve Months Ending 2021-03
Industry PE 34.39 Trailing Twelve Months Ending 2021-03
Book Value / Share 227.20 Trailing Twelve Months Ending 2021-03
Price to Book Value 3.88 Calculated using Price: 882.30
Dividend Yield 0.57 Period Ending 2020-03
No. of Shares Subscribed 80.66 Cr. 806,642,457 Shares
FaceValue 2
Company Profile

Cipla Limited is a global pharmaceutical company focused on responsible and sustainable growth of complex generics and deepening portfolio in home markets of India, South Africa and North America, as well as key regulated and emerging markets. Equity Shares of the Company are listed on Bombay Stock Exchange Limited and National Stock Exchange of India Limited.

Business area of the company

The company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company has its wide network of manufacturing, trading and other incidental operations in India and International markets.

Products

  • Generics and branded generics
  • Specialty
  • Consumer health

Awards:

2013:

  • Ernst & Young awarded Dr. Y K Hamied with the Lifetime Achievement Award of the year 2013
  • Dr. Hamied honoured with the Greatest Global Indian Living Legend Award by NDTV
  • Viragaonagar unit won the Excellence Award in Environment Health & Safety (EHS)
  • Bagged the prestigious LegalEra Award for the Best Pharmaceutical in-house Legal team.

2014

  • Cipla won the Global L&D Team of the Year Award
  • Brand, Azee bagged the Marketing Excellence Award in 2014
  • Won the 'Silver' award from Pharmexcil for Outstanding Performance in the export of Pharmaceuticals
  • Network 18 and Infosys awarded Cipla for innovation on HIV/AIDS drugs

2015:

  • Won the Award for Excellence in Rural Reach at India Pharma Awards
  • Accredited to be in Top 10 of Hot 50 Brands in Mumbai, under ‘Large Organization Category’ at the Mumbai Brand Summit
  • Won the Social Contributors Award at the Annual Pitch Top 50 Brands Awards organized by Dainik Bhaskar
  • Best Company Award to focus in Overall Nursing Home Development at the first ever CIMS Healthcare Excellence Awards
  • ABP News honored Dr. Y.K. Hamied with the ‘Lifetime Achievement Award’ at the Brand Excellence Awards 2015

2016:

  • The Indian Manufacturers’ Association (IDMA) honoured Dr. Hamied with IDMA Lifetime Achievement Award for his outstanding contribution to the Indian pharmaceutical industry.
  • Moroccan Society of ENT honoured Cipla Morocco team for contribution to the education of the physics.
  • Dr. Y.K. Hamied was honoured with the Lifetime Achievement Award at the Forbes India Leadership Awards 2016.
  • Won two awards for Supplier Relationship Management and People Management at the CPO Awards 2016
  • Received an award for Acnedep Gel packaging at the 'India Packaging Awards' 2016
  • Won the ABP News Healthcare Leadership Award for excellence in managing Primary Care Practitioners

2017:

  • Digital team bagged two of the most prestigious awards of the digital world - Digital Pioneer of the year 2017 and Best company for leveraging technology in mobile application.
  • ActivKids Immuno Boosters won the Emerging Nutrition Brand of the Year awarded by CIMS.
  • Cipla Health won a place in the Economic Times Best Asian Healthcare Brands 2017

2018:

  • India Packaging Awards for Excellence in Enhanced User Experience for Mesalo Foam packaging
  • Silver Plasticon Award 2018 for Excellence and Innovation in flexible packaging for Acnedap Plus
  • SCMPro Logistics and Supply Chain Awards for 'Excellence in Pharma Supply Chain Management, Procurement Transformation of the Year' and 'Best Sourcing Analytics'.
  • Global Logistics Excellence Award for 'Best Digital Transformation in Pharma' in the Supply Chain Practitioners category
  • Breathefree website bags DMA Asia Echo Award (Silver) for Best Digital Destination and Leader Certificate in Pharma & Healthcare category
  • India Pharma Awards for Breathefree - 'Best Patient Outreach Programme of the Year', Digital Innovation
  • Indian Digital Awards (IDA) for Excellence in Digital Publishing
  • ABP News Healthcare Leadership Award for Excellence in Improving Awareness, Detection of Health Issues and Adherence to Treatment Regimen in the Emerging Markets

2019:

  • Cipla receives the 18th ICSI (Institute of Company Secretaries of India) National Award for Excellence in Corporate Governance in January 2019.
  • Highly Commended - 'Best Working Capital Management Solution Award' at the Adam Smith Awards Asia 2019
  • 'Innovation in Generics' Award for Sereflo at the UK Pharmacy Business Awards 2019
  • ‘Indo-American Corporate Excellence Award' for Excellence in Manufacturing (Category II) by the Indo-American Chamber of Commerce
  • Most Outstanding Company in India - Healthcare category at the Asiamoney Asia’s Outstanding Companies Poll 2019

2020:

  • Cipla Sri Lanka is Great Place to Work Certified
  • Cipla is Great Place to Work Certified
  • ‘Digital Supply Chain Enterprise Award’ at the 9th edition of the Manufacturing Supply Chain Awards 2020
  • Golden Peacock Award for CSR 2019 in recognition of Cipla Foundation's significant contribution towards social change
  • What’s Up Cipla bags the 'Best Small Idea, Big Impact Communication of the Year' at the Corp Comm & PR Excellence Awards 2020
  • The Institute of Chartered Accountants of India Award for Excellence in Financial Reporting 2018-19 under the category of companies publishing integrated annual report

Milestones

  • 1935: Operations commence from a rented bungalow at 289, Bellasis Road, Bombay Central.
  • 1939: Mahatma Gandhi visits Cipla, inspiring the Founder Dr K A Hamied to produce vital and life-saving medicines for India.
  • 1947: Cipla celebrates India attaining Independence with a flag hoisting ceremony at Bombay Central Headquarters.
  • 1970: Cipla becomes one of the pioneers to manufacture APIs (active pharmaceutical ingredients).
  • 1977: Inauguration of the Cipla Research and Production Complex in Bangalore by Mrs. Luba K Hamied.
  • 1997: Cipla Palliative Care and Training Centre is set up in Pune to provide free holistic care to terminally-ill cancer patients and their families.
  • 2001: Cipla ushers in a new paradigm in antiretroviral therapy (ART) by offering the triple ARV FDC at USD 1-a-day, thus opening the floodgates for affordability and accessibility in HIV/AIDS treatment.
  • 2013: Cipla acquires 100% of share capital of Cipla Medpro (South Africa).
  • 2016: Cipla strengthens its presence in the US market with the acquisition of InvaGen Pharmaceuticals Inc. and Exelan Pharmaceuticals Inc. thus expanding its reach in the US market, with a balanced portfolio.
  • 2017: Cipla launches Synchrobreathe, a state of-the-art innovative breath-actuated inhaler, helping millions with Obstructive Airway Diseases such as asthma.
  • 2019: Cipla enters digital therapeutics by partnering with Wellthy Therapeutics in India and Brandmed in South Africa to bring together behavioural science, real world clinical evidence and artificial intelligence to provide real time monitoring, coaching and advice to patients.
  • 2020: Cipla leads the fight against COVID-19 through a spectrum of vital drugs that show potency against the virus. With unmatched portfolio of drugs and devices and leadership across India and key emerging markets, Cipla launches global lung leadership aspiration - Breathe. Think Cipla. In the US, the approval for generic AIbuterol MDI and successful Phase-3 completion of clinical study for generic Advair Diskus furthers this ambition.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+4.31%
1 Week
-2.92%
1 Month
-5.31%
3 Month
+0.99%
6 Month
+11.47%
1 Year
+34.16%
2 Year
+76.93%
5 Year
+74.25%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 15.98 18.64 14.89 12.10 12.61 8.72 10.65 10.37 10.09
Return on Capital Employed (%) 19.96 24.15 19.05 15.33 13.24 8.28 10.20 11.94 12.53
Return on Assets (%) 12.05 13.97 10.49 7.85 7.28 4.97 6.52 6.50 6.56

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 7,639 9,019 10,050 10,801 11,516 12,544 14,229 15,012 15,763
Non Curr. Liab. 824 1,025 2,028 2,418 1,407 4,515 4,259 4,646 2,972
Curr. Liab. 1,413 2,278 2,564 3,881 7,776 3,389 3,832 3,772 4,393
Minority Int. 50 180 350 438 352 332 294
Equity & Liab. 9,876 12,321 14,692 17,281 21,049 20,886 22,673 23,762 23,423
Non Curr. Assets 4,820 5,537 9,040 9,689 12,208 12,082 11,859 11,335 11,717
Curr. Assets 5,057 6,784 5,652 7,591 8,841 8,804 10,814 12,427 11,706
Misc. Exp. not W/O
Total Assets 9,876 12,321 14,692 17,281 21,049 20,886 22,673 23,762 23,423

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 7,021 8,279 10,173 11,345 13,595 14,394 15,156 16,362 17,132
Other Income 140 222 265 166 208 229 358 477 369
Total Income 7,160 8,501 10,439 11,511 13,803 14,623 15,513 16,839 17,501
Total Expenditure -5,362 -6,081 -8,040 -9,184 -11,115 -11,919 -12,702 -13,494 -14,026
PBIDT 1,798 2,420 2,398 2,327 2,688 2,704 2,811 3,345 3,475
Interest -38 -34 -146 -168 -207 -159 -114 -168 -197
Depreciation -312 -330 -373 -505 -754 -1,323 -950 -1,097 -1,100
Taxation -307 -544 -463 -400 -332 -180 -250 -570 -631
Exceptional Items 40 -78
PAT 1,141 1,551 1,417 1,254 1,395 1,042 1,419 1,510 1,547

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 1,713 1,398 1,563 1,173 1,741 2,382 1,463 1,691 3,068
Cash Fr. Inv. -965 -2,063 -1,250 -941 -4,523 -1,310 -854 -1,669 104
Cash Fr. Finan. -753 718 -266 165 3,104 -1,326 -385 -349 -2,949
Net Change -6 53 48 397 322 -254 223 -326 224
Cash & Cash Eqvt 90 143 176 564 858 610 853 508 742

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 36.70 36.68 36.68 36.68 36.68 36.70 36.70 36.73 36.72
Public 63.30 63.32 63.32 63.32 63.32 63.30 63.30 63.27 63.28
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Thu, 29 Jul 2021
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation for loss of share certificates.
Wed, 28 Jul 2021
Earnings Conference Call
Please find enclosed schedule of Earnings Conference Call to be held on 5th August 2021.
Tue, 27 Jul 2021
Announcement under Regulation 30 (LODR)-Newspaper Publication

Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 and in compliance with various circulars issued by the Ministry of Corporate Affairs we hereby enclose copies of newspaper advertisement published in Business Standard (English) and Sakal (Marathi) on 27th July 2021 intimating the shareholders about the Annual General Meeting E-voting Record date and Dividend.

Technical Scans View Details

Thu, 29 Jul 2021
Stock Underperforming Benchmark Index in both 1 Week and 3 Month Stock Underperforming Benchmark Index in both 1 Week and 3 Month
Stock Underperforming Sectoral Index in both 1 Week and 3 Month Stock Underperforming Sectoral Index in both 1 Week and 3 Month
Decreasing Relative Strength - Benchmark index Decreasing Relative Strength - Benchmark index
Close Within 2 Year High Zone Close Within 2 Year High Zone
Close Within 5 Year High Zone Close Within 5 Year High Zone

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,733.23 774.00 +10.1%
Divi's Laboratories Ltd. 128,656.69 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. 77,707.65 4,712.70 +0.9%
Cadila Healthcare Ltd. 58,547.84 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. 58,067.43 4,025.00 -0.3%
Aurobindo Pharma Ltd. 53,214.94 916.50 +0.9%
Piramal Enterprises Ltd. 52,639.21 2,323.00 +0.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.11 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 64.84 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 44.73 4,712.70 +0.9%
Cadila Healthcare Ltd. Consolidated 2021-03 27.44 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 386.19 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 9.98 916.50 +0.9%
Piramal Enterprises Ltd. Consolidated 2021-03 39.51 2,323.00 +0.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 13.84 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.35 4,712.70 +0.9%
Cadila Healthcare Ltd. Consolidated 2021-03 4.51 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.64 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.43 916.50 +0.9%
Piramal Enterprises Ltd. Consolidated 2021-03 1.54 2,323.00 +0.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,712.70 +0.9%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 916.50 +0.9%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,323.00 +0.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,712.70 +0.9%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 916.50 +0.9%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,323.00 +0.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,712.70 +0.9%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 916.50 +0.9%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,323.00 +0.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,712.70 +0.9%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 916.50 +0.9%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,323.00 +0.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,712.70 +0.9%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 916.50 +0.9%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,323.00 +0.2%